Immunological and Autoimmune Disorders

For Inflectra launch, Pfizer uses 'hybrid model' to home in on HCPs Pfizer hit the market with Inflectra, a biosimilar of Johnson & Johnson's Remicade. And with the launch came not only the beginning of a new class of copycats, but a new way to go to market. Each biosimilar, even versions of the same biologic—while required to be “highly similar”—are technically different and come with different datasets and proof points. So, Pfizer went to work to create a new “hybrid model” to bring biosimilars to market. Through this model, each biosimilar brand launch will be customized, each will also leverage the scale of the model platform. US FDA approves Rubraca to treat a...